Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  HIV Infection

  Free Subscription


Articles published in HIV Med

Retrieve available abstracts of 300 articles:
HTML format



Single Articles


    September 2022
  1. LE LT, Price RW, Gisslen M, Zetterberg H, et al
    Correlation between CD4/CD8 ratio and neurocognitive performance during early HIV infection.
    HIV Med. 2022 Sep 22. doi: 10.1111/hiv.13411.
    PubMed     Abstract available


  2. FITZPATRICK C, Richardson D, Sherriff N, Whetham J, et al
    Pilot evaluation of PrEP EmERGE - A novel digital health innovation designed to support sexual health clinics and HIV-PrEP users.
    HIV Med. 2022 Sep 22. doi: 10.1111/hiv.13406.
    PubMed     Abstract available


  3. HIKASA S, Shimabukuro S, Hideta K, Higasa S, et al
    Comparison between the impact of tenofovir alafenamide and that of abacavir on rapid kidney function decline: A retrospective observational study.
    HIV Med. 2022 Sep 20. doi: 10.1111/hiv.13408.
    PubMed     Abstract available


  4. MCGETTIGAN P, Morales DR, Moreno-Martos D, Matin N, et al
    Changing co-morbidity and increasing deprivation among people living with HIV: UK population-based cross-sectional study.
    HIV Med. 2022 Sep 19. doi: 10.1111/hiv.13389.
    PubMed     Abstract available


  5. SHAPIRO AE, Tenforde MW, Chiller TM, Ford N, et al
    An updated systematic review of HIV-associated cryptococcal meningitis treatment strategies.
    HIV Med. 2022 Sep 19. doi: 10.1111/hiv.13412.
    PubMed     Abstract available


  6. ZHANG Q, Jiao YM, Li G, Zhang LX, et al
    Serum globulin levels are associated with HIV reservoir size and immune restoration during long-term ART.
    HIV Med. 2022 Sep 13. doi: 10.1111/hiv.13393.
    PubMed     Abstract available


  7. ABIOYE AI, Sudfeld CR, Hughes MD, Aboud S, et al
    Iron status among HIV-infected adults during the first year of antiretroviral therapy in Tanzania.
    HIV Med. 2022 Sep 8. doi: 10.1111/hiv.13396.
    PubMed     Abstract available


  8. KIRWAN PD, Croxford S, Aghaizu A, Murphy G, et al
    Re-assessing the late HIV diagnosis surveillance definition in the era of increased and frequent testing.
    HIV Med. 2022 Sep 7. doi: 10.1111/hiv.13394.
    PubMed     Abstract available


  9. FULLER T, Fragoso da Silveira Gouvea MI, Benamor Teixeira ML, Ferreira Medeiros A, et al
    Real-world experience with weight gain among pregnant women living with HIV who are using integrase inhibitors.
    HIV Med. 2022 Sep 5. doi: 10.1111/hiv.13388.
    PubMed     Abstract available


  10. HOFFMANN C, Jessen H, Wyen C, Grunwald S, et al
    Clinical characteristics of monkeypox virus infections among men with and without HIV: A large outbreak cohort in Germany.
    HIV Med. 2022 Sep 4. doi: 10.1111/hiv.13378.
    PubMed     Abstract available


    August 2022
  11. KABLAWI D, Alhinai A, Wong P, Deschenes M, et al
    Splenomegaly is a marker of advanced chronic liver disease and portal hypertension in HIV infection.
    HIV Med. 2022 Aug 30. doi: 10.1111/hiv.13390.
    PubMed     Abstract available


  12. AKSAK-WAS BJ, Kowalska JD, Zabek P, Serwin K, et al
    Immune restoration affects 10-year survival in people living with HIV/AIDS.
    HIV Med. 2022 Aug 25. doi: 10.1111/hiv.13391.
    PubMed     Abstract available


  13. BALUKU JB, Nabwana M, Mwanahamisi SB, Kansiime G, et al
    Early culture conversion is a poor marker of treatment outcome among people with HIV and drug-resistant TB.
    HIV Med. 2022 Aug 22. doi: 10.1111/hiv.13392.
    PubMed     Abstract available


  14. OCEGUERA S, Tulloch K, Tkachuk S
    Post-partum contraception in women living with HIV.
    HIV Med. 2022 Aug 16. doi: 10.1111/hiv.13371.
    PubMed     Abstract available


  15. SHAFRAN SD, Hughes CA
    Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance.
    HIV Med. 2022 Aug 16. doi: 10.1111/hiv.13376.
    PubMed     Abstract available


  16. D'AMICO R, Cenoz Gomis S, Moodley R, Van Solingen-Ristea R, et al
    Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy.
    HIV Med. 2022 Aug 9. doi: 10.1111/hiv.13370.
    PubMed     Abstract available


  17. PERELLO R, Losada A, Chen J, Supervia A, et al
    Amphetamine-related intoxications in people living with HIV: An observational study in an emergency department in Barcelona (Spain) from 2018 to 2020.
    HIV Med. 2022 Aug 9. doi: 10.1111/hiv.13365.
    PubMed     Abstract available


  18. LIONS C, Laroche H, Mora M, Pialoux G, et al
    Missed opportunities for HIV pre-exposure prophylaxis among people with recent HIV infection: The French ANRS 95041 OMaPrEP study.
    HIV Med. 2022 Aug 9. doi: 10.1111/hiv.13367.
    PubMed     Abstract available


  19. NASREDDINE R, Yombi JC, Darcis G, Florence E, et al
    Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.
    HIV Med. 2022 Aug 8. doi: 10.1111/hiv.13373.
    PubMed     Abstract available


  20. NIKOLAICHUK M, Mocroft A, Wandeler G, Szlavik J, et al
    Use of contraindicated antiretroviral drugs in people with HIV/HCV coinfections receiving HCV treatment with direct-acting antivirals-Results from the EuroSIDA study.
    HIV Med. 2022 Aug 8. doi: 10.1111/hiv.13357.
    PubMed     Abstract available


  21. GARCIA YD, Urena FA, Carrion-Nessi FS, Diaz SY, et al
    HBV, HCV, or syphilis coinfection with HIV in pregnant women seen at the main hospital in the capital of Venezuela.
    HIV Med. 2022 Aug 7. doi: 10.1111/hiv.13372.
    PubMed    


  22. GOODEN TE, Wang J, Zemedikun DT, Taylor S, et al
    A matched cohort study investigating premature, accentuated, and accelerated aging in people living with HIV.
    HIV Med. 2022 Aug 7. doi: 10.1111/hiv.13375.
    PubMed     Abstract available


  23. GARCIA JM, Dong Y, Richardson P, Kramer JR, et al
    Effect of HIV and antiretroviral therapy use on body weight changes in a cohort of U.S. veterans living with and without HIV.
    HIV Med. 2022 Aug 5. doi: 10.1111/hiv.13366.
    PubMed     Abstract available


  24. KING EM, Swann SA, Murray MCM
    Markers of ovarian reserve in women living with HIV: A systematic review.
    HIV Med. 2022 Aug 2. doi: 10.1111/hiv.13364.
    PubMed     Abstract available


    July 2022
  25. SCHUETTFORT G, Groh A, Kann G, Haberl A, et al
    Sexually transmitted diseases in people living with HIV after implementation of cost coverage of HIV pre-exposure prophylaxis by statutory health insurance in Germany.
    HIV Med. 2022 Jul 20. doi: 10.1111/hiv.13353.
    PubMed     Abstract available


  26. TSAKONA D, Kapetanakis A, Kyrou D, Vrontaras N, et al
    Mapping frailty in people living with HIV: A nationwide study in Greece.
    HIV Med. 2022 Jul 15. doi: 10.1111/hiv.13356.
    PubMed     Abstract available


  27. RACCAGNI AR, Bruzzesi E, Calzavara D, Vinti P, et al
    HIV-NAAT use for early detection of HIV infection among high-risk men who have sex with men in Italy.
    HIV Med. 2022 Jul 15. doi: 10.1111/hiv.13363.
    PubMed    


  28. GILL RC, Levett T, Youssef E
    An audit of HIV testing practice in people aged 50 years and over presenting with a known clinical indicator condition in secondary care.
    HIV Med. 2022 Jul 10. doi: 10.1111/hiv.13355.
    PubMed     Abstract available


  29. EU B, Dawe J, Dunn M, Lee K, et al
    Are there additional adverse effects of testosterone use among men living with HIV?-Data from the PUSH! study.
    HIV Med. 2022 Jul 2. doi: 10.1111/hiv.13354.
    PubMed    



  30. Erratum.
    HIV Med. 2022;23:701.
    PubMed    


    June 2022
  31. LI M, Wang Q
    Predicting the loss to follow-up (LTFU) of HIV/AIDS patients in China using a recency-frequency (RF) model.
    HIV Med. 2022 Jun 27. doi: 10.1111/hiv.13324.
    PubMed     Abstract available


  32. KHUON D, Rupasinghe D, Saphonn V, Kwong TS, et al
    BMI as a predictor of high fasting blood glucose among people living with HIV in the Asia-Pacific region.
    HIV Med. 2022 Jun 24. doi: 10.1111/hiv.13351.
    PubMed     Abstract available


  33. BROWN JA, Nsakala BL, Mokhele K, Rakuoane I, et al
    Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho.
    HIV Med. 2022 Jun 22. doi: 10.1111/hiv.13352.
    PubMed     Abstract available


  34. SIMMONS R, Plunkett J, Cieply L, Ijaz S, et al
    Blood-borne virus testing in emergency departments - a systematic review of seroprevalence, feasibility, acceptability and linkage to care.
    HIV Med. 2022 Jun 14. doi: 10.1111/hiv.13328.
    PubMed     Abstract available


  35. CARVALHO S, Lee T, Tulloch KJ, Sauve LJ, et al
    Prescribing patterns of antiretroviral treatments during pregnancy for women living with HIV in Canada 2004-2020: A surveillance study.
    HIV Med. 2022 Jun 14. doi: 10.1111/hiv.13346.
    PubMed     Abstract available


  36. SIDDIQI KA, Ostermann J, Zhang J, Khan MM, et al
    Ageing with HIV in the United States: Changing trends in inpatient hospital stays and comorbidities, 2003-2015.
    HIV Med. 2022 Jun 8. doi: 10.1111/hiv.13325.
    PubMed     Abstract available


  37. SEXTON H, Kumarendran M, Brandon Z, Shi C, et al
    Adverse perinatal outcomes associated with timing of initiation of antiretroviral therapy: Systematic review and meta-analysis.
    HIV Med. 2022 Jun 6. doi: 10.1111/hiv.13326.
    PubMed     Abstract available


  38. PULA J, Kowalska J, Paciorek M, Bednarska A, et al
    Late diagnosis of HIV infection in Warsaw: Estimating the scale of the problem and demographic trends.
    HIV Med. 2022 Jun 6. doi: 10.1111/hiv.13323.
    PubMed     Abstract available


    May 2022
  39. ANDERSON K, Pietersen E, Shepherd BE, Bian A, et al
    High mortality among patients hospitalized for drug-resistant tuberculosis with acquired second-line drug resistance and high HIV prevalence.
    HIV Med. 2022 May 24. doi: 10.1111/hiv.13318.
    PubMed     Abstract available


  40. GIZAW A, King WC, Hinerman AS, Chung RT, et al
    A prospective cohort study of renal function and bone turnover in adults with hepatitis B virus (HBV)-HIV co-infection with high prevalence of tenofovir-based antiretroviral therapy use.
    HIV Med. 2022 May 16. doi: 10.1111/hiv.13322.
    PubMed     Abstract available


  41. YU H, Yang Y, Cao D, Zhao Y, et al
    Association of low-level viremia with mortality among people living with HIV on antiretroviral therapy in Dehong, Southwest China: A retrospective cohort study.
    HIV Med. 2022 May 16. doi: 10.1111/hiv.13320.
    PubMed     Abstract available


  42. MAGGIOLO F, Rizzardini G, Molina JM, Pulido F, et al
    Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people >/=65 years of age.
    HIV Med. 2022 May 8. doi: 10.1111/hiv.13319.
    PubMed     Abstract available


  43. TINGGAARD M, David KP, Gerstoft J, Hansen AE, et al
    Potential drug-drug interactions between antiretroviral drugs and comedications, including dietary supplements, among people living with HIV: A clinical survey.
    HIV Med. 2022 May 6. doi: 10.1111/hiv.13321.
    PubMed     Abstract available


  44. GRIMSHAW C, Trayner KMA
    Editorial on 'Epidemiology of HIV infection and associated behaviours among people who inject drugs in England, Wales, and Northern Ireland: nearly 40 years on'.
    HIV Med. 2022 May 4. doi: 10.1111/hiv.13300.
    PubMed    


    April 2022
  45. BONJOCH A, Juega J, Echeverria P, Puig J, et al
    Prevalence, progression, and management of advanced chronic kidney disease in a cohort of people living with HIV.
    HIV Med. 2022 Apr 26. doi: 10.1111/hiv.13317.
    PubMed     Abstract available


  46. HOUSSEIN M, Inkaya AC, Balci C, Esme M, et al
    Frailty and sarcopenia among Turkish people aged 40 and above living with HIV.
    HIV Med. 2022 Apr 19. doi: 10.1111/hiv.13311.
    PubMed     Abstract available


  47. WHITLOCK GG, Ahmed N, Nori A, Richardson D, et al
    Characteristics of HIV post-exposure prophylaxis recipients at six English sexual health clinics during COVID-19.
    HIV Med. 2022 Apr 10. doi: 10.1111/hiv.13308.
    PubMed     Abstract available


  48. TANG ME, Gaufin T, Anson R, Zhu W, et al
    People with HIV have a higher risk of COVID-19 diagnosis but similar outcomes to the general population.
    HIV Med. 2022 Apr 8. doi: 10.1111/hiv.13312.
    PubMed     Abstract available


  49. DRAK D, Heron JE, Shamu T, Chimbetete C, et al
    Predictors of renal impairment and proteinuria after commencement of antiretroviral therapy in a Zimbabwean HIV cohort.
    HIV Med. 2022 Apr 8. doi: 10.1111/hiv.13303.
    PubMed     Abstract available


  50. MOSEHOLM E, Katzenstein TL, Pedersen G, Johansen IS, et al
    Use of antiretroviral therapy in pregnancy and association with birth outcome among women living with HIV in Denmark: A nationwide, population-based cohort study.
    HIV Med. 2022 Apr 6. doi: 10.1111/hiv.13304.
    PubMed     Abstract available


  51. LOUW S, Jacobson BF, Wiggill TM, Chapanduka Z, et al
    HIV-associated thrombotic thrombocytopenic purpura (HIV-TTP): A practical guide and review of the literature.
    HIV Med. 2022 Apr 3. doi: 10.1111/hiv.13305.
    PubMed     Abstract available


  52. CHIRWA M, Taghinejadi N, Macaulay G, Mandalia S, et al
    Reflections on a specialist HIV menopause service: Experiences of managing menopause in women living with HIV: Experiences of managing menopause in women living with HIV.
    HIV Med. 2022;23:426-433.
    PubMed     Abstract available


  53. GILLEECE Y, Sabin CA
    Special issue on Women and HIV to mark International Women's Day.
    HIV Med. 2022;23:309.
    PubMed    



  54. BHIVA Spring Conference 2022, Manchester Central, Manchester, UK, 20-22 April 2022.
    HIV Med. 2022;23 Suppl 2:3-95.
    PubMed    


    March 2022
  55. TEKALIGN T, Awoke N, Eshetu K, Gelaw Walle B, et al
    HIV/AIDS post-exposure prophylaxis knowledge and uptake among health professionals in Africa: Systematic review and meta-analysis.
    HIV Med. 2022 Mar 30. doi: 10.1111/hiv.13271.
    PubMed     Abstract available


  56. CROXFORD S, Emanuel E, Shah A, Chau C, et al
    Epidemiology of HIV infection and associated behaviours among people who inject drugs in England, Wales, and Northern Ireland: Nearly 40 years on.
    HIV Med. 2022 Mar 30. doi: 10.1111/hiv.13297.
    PubMed     Abstract available


  57. COCKBAIN B, Whitlock G
    Immediate PrEP when accessing PEP: A service evaluation.
    HIV Med. 2022 Mar 29. doi: 10.1111/hiv.13310.
    PubMed     Abstract available


  58. SHANKS G, Shah A, Williams A, Asboe D, et al
    Covid-19 First Wave Impact National Survey for HIV Clinicians by Public Health England (PHE), the British HIV Association (BHIVA) and the Children's HIV Association (CHIVA).
    HIV Med. 2022 Mar 28. doi: 10.1111/hiv.13307.
    PubMed     Abstract available


  59. LUU B, Ruderman S, Nance R, Delaney JAC, et al
    Tobacco smoking and binge alcohol use are associated with incident venous thromboembolism in an HIV cohort.
    HIV Med. 2022 Mar 28. doi: 10.1111/hiv.13309.
    PubMed     Abstract available


  60. SWANN SA, King EM, Cote HCF, Murray MCM, et al
    Stressing the need for validated measures of cortisol in HIV research: A scoping review.
    HIV Med. 2022 Mar 27. doi: 10.1111/hiv.13272.
    PubMed     Abstract available


  61. HENRIQUES BL, Cortez AL, Nunes NN, Vidal JE, et al
    Clinical outcomes of HIV-syphilis coinfection among patients with no neurological symptoms: a retrospective cohort study.
    HIV Med. 2022 Mar 27. doi: 10.1111/hiv.13306.
    PubMed     Abstract available


  62. RYOM L, De Miguel R, Cotter AG, Podlekareva D, et al
    Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021.
    HIV Med. 2022 Mar 25. doi: 10.1111/hiv.13268.
    PubMed     Abstract available


  63. ANDERSEN MH, Alexander MT, Bintz C, Ford C, et al
    Medically assisted reproduction for people living with HIV in Europe: A cross-country exploratory policy comparison.
    HIV Med. 2022 Mar 22. doi: 10.1111/hiv.13269.
    PubMed     Abstract available


  64. GEDELA K, Rajus N, Luis H, Fridayantara WD, et al
    Antiretroviral drug switches to zidovudine-based regimens and loss to follow-up during the first COVID-19 lockdown in Bali, Indonesia.
    HIV Med. 2022 Mar 21. doi: 10.1111/hiv.13298.
    PubMed     Abstract available


  65. FRANGE P, Avettand-Fenoel V, Veber F, Blanche S, et al
    No overall impact on body mass index for age change after dolutegravir initiation in a French paediatric cohort.
    HIV Med. 2022 Mar 20. doi: 10.1111/hiv.13302.
    PubMed     Abstract available


  66. LEE KW, Ang CS, Lim SH, Siau CS, et al
    Prevalence of mental health conditions among people living with HIV during the COVID-19 pandemic: A rapid systematic review and meta-analysis.
    HIV Med. 2022 Mar 18. doi: 10.1111/hiv.13299.
    PubMed     Abstract available


  67. HE J, Shi R, Duan S, Ye R, et al
    Microbial translocation is associated with advanced liver fibrosis among people with HIV.
    HIV Med. 2022 Mar 17. doi: 10.1111/hiv.13279.
    PubMed     Abstract available


  68. PEREZ-VALERO I, Blanch J, Martinez E
    Perception of HIV physicians in Spain towards diagnosis and management of neuropsychiatric comorbidities in people with HIV.
    HIV Med. 2022 Mar 16. doi: 10.1111/hiv.13296.
    PubMed     Abstract available


  69. ORKIN C, Cahn P, Castagna A, Emu B, et al
    Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment-limited individuals living with HIV.
    HIV Med. 2022 Mar 16. doi: 10.1111/hiv.13288.
    PubMed     Abstract available


  70. AGUSTI C, Cunillera O, Almeda J, Mascort J, et al
    Efficacy of an electronic reminder for HIV screening in primary healthcare based on indicator conditions in Catalonia (Spain).
    HIV Med. 2022 Mar 13. doi: 10.1111/hiv.13270.
    PubMed     Abstract available


  71. CICCONI P, Wells C, McCarthy B, Wareing S, et al
    Re-valuation of annual cytology using HPV self-sampling to upgrade prevention (REACH UP): A feasibility study in women living with HIV in the UK.
    HIV Med. 2022 Mar 3. doi: 10.1111/hiv.13257.
    PubMed     Abstract available


  72. RAFFE S, Sabin C, Gilleece Y
    Comorbidities in women living with HIV: A systematic review.
    HIV Med. 2022 Mar 3. doi: 10.1111/hiv.13240.
    PubMed     Abstract available


  73. ALVAREZ H, Rava M, Martinez C, Portilla J, et al
    Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort.
    HIV Med. 2022 Mar 1. doi: 10.1111/hiv.13265.
    PubMed     Abstract available


  74. BYONANEBYE DM, Polizzotto MN, Neesgaard B, Sarcletti M, et al
    Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium.
    HIV Med. 2022 Mar 1. doi: 10.1111/hiv.13273.
    PubMed     Abstract available


  75. RAPITI N, Peer N, Abdelatif N, Rapiti P, et al
    HIV-associated plasmablastic lymphoma: A single-centre 12-year experience in Kwa-Zulu Natal, South Africa.
    HIV Med. 2022 Mar 1. doi: 10.1111/hiv.13266.
    PubMed     Abstract available


  76. DUAN Y, Zhao H, Tang W, Chen M, et al
    Longitudinal analysis of new-onset non-AIDS-defining diseases among people living with HIV: A real-world observational study.
    HIV Med. 2022;23 Suppl 1:32-41.
    PubMed     Abstract available


  77. LI J, Li A, Ye J, Shao Y, et al
    Loss to follow-up among human immunodeficiency virus-positive postpartum women and its predictive factors: A retrospective study.
    HIV Med. 2022;23 Suppl 1:42-53.
    PubMed     Abstract available


  78. JIAO YM, Xu Z, Wang FS
    Snapshot of clinical problems among people living with HIV in China.
    HIV Med. 2022;23 Suppl 1:4-5.
    PubMed    


  79. HUANG H, Song B, Gao L, Cheng J, et al
    Incidence of and risk factors for liver damage in patients with HIV-1 mono-infection receiving antiretroviral therapy.
    HIV Med. 2022;23 Suppl 1:14-22.
    PubMed     Abstract available


  80. MA J, Zheng Q, Zhang H, Wen Y, et al
    The spectrum of kidney biopsy findings in Chinese HIV-infected patients.
    HIV Med. 2022;23 Suppl 1:23-31.
    PubMed     Abstract available


  81. NIE J, Deng X, Zeng Q, Du X, et al
    Distribution of nontuberculous mycobacteria in patients with and without HIV/AIDS in Chongqing.
    HIV Med. 2022;23 Suppl 1:54-63.
    PubMed     Abstract available


  82. DING H, Xu J, Liu J, Wang Q, et al
    Outcomes of persistent low-level viremia among HIV patients on antiretroviral therapy: A prospective cohort study.
    HIV Med. 2022;23 Suppl 1:64-71.
    PubMed     Abstract available


  83. BAI R, Lv S, Hua W, Su B, et al
    Factors associated with human immunodeficiency virus-1 low-level viremia and its impact on virological and immunological outcomes: A retrospective cohort study in Beijing, China.
    HIV Med. 2022;23 Suppl 1:72-83.
    PubMed     Abstract available


  84. MIJITI Z, Song JW, Jiao YM, Gao L, et al
    alpha4beta7(high) CD4(+) T cells are prone to be infected by HIV-1 and associated with HIV-1 disease progression.
    HIV Med. 2022;23 Suppl 1:106-114.
    PubMed     Abstract available


  85. QIN Y, Song T, Su B, Jiao Y, et al
    Comparison of HIV DNA decay and immune recovery between early and chronic HIV-infected individuals 96 weeks after ART.
    HIV Med. 2022;23 Suppl 1:6-13.
    PubMed     Abstract available


  86. GAO L, Xia H, Zeng R, Wu Y, et al
    Pre-treatment and acquired antiretroviral drug resistance among people living with HIV in Tianjin, China.
    HIV Med. 2022;23 Suppl 1:84-94.
    PubMed     Abstract available


  87. LIU M, He XQ, Deng RN, Tang SQ, et al
    Pretreatment drug resistance in people living with HIV: A large retrospective cohort study in Chongqing, China.
    HIV Med. 2022;23 Suppl 1:95-105.
    PubMed     Abstract available


    February 2022
  88. BAISLEY K, Orne-Gliemann J, Larmarange J, Plazy M, et al
    Treat-all strategy and long-term survival among people living with HIV in South Africa: Results after 6 years of observation in the ANRS 12249 treatment as prevention trial.
    HIV Med. 2022 Feb 26. doi: 10.1111/hiv.13263.
    PubMed     Abstract available


  89. RUPASINGHE D, Choi JY, Kumarasamy N, Pujari S, et al
    Viral hepatitis and the cascade of care among people living with HIV in the Asia-Pacific.
    HIV Med. 2022 Feb 25. doi: 10.1111/hiv.13280.
    PubMed     Abstract available


  90. HULLY A, Mallah R, Villa G, Gilleece Y, et al
    Integrating services to improve quality of care for women living with HIV: A global systematic review.
    HIV Med. 2022 Feb 24. doi: 10.1111/hiv.13258.
    PubMed     Abstract available


  91. ROSSETTI B, Fabbiani M, Di Carlo D, Incardona F, et al
    Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe.
    HIV Med. 2022 Feb 24. doi: 10.1111/hiv.13262.
    PubMed     Abstract available


  92. CERVO A, Sebastiani G, Milic J, Krahn T, et al
    "Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV".
    HIV Med. 2022 Feb 24. doi: 10.1111/hiv.13274.
    PubMed     Abstract available


  93. ODONGPINY ELA, Cresswell F, Arinaitwe A, Nakate V, et al
    High willingness to use injectable antiretroviral therapy among women who have been lost to follow-up from HIV programmes: A nested cross-sectional study.
    HIV Med. 2022 Feb 23. doi: 10.1111/hiv.13260.
    PubMed     Abstract available


  94. HACHFELD A, Atkinson A, Stute P, Calmy A, et al
    Women with HIV transitioning through menopause: Insights from the Swiss HIV Cohort Study (SHCS).
    HIV Med. 2022 Feb 22. doi: 10.1111/hiv.13255.
    PubMed     Abstract available


  95. LEE MJ, Nori A, Fidler S, Kulasegaram R, et al
    Response to 'The use of tenofovir in patients with COVID-19'.
    HIV Med. 2022 Feb 22. doi: 10.1111/hiv.13278.
    PubMed    


  96. LACOMBE-DUNCAN A, Shokoohi M, Persad Y, Underhill A, et al
    Short report: Characterizing HIV care among a clinical sample of transgender women living with HIV.
    HIV Med. 2022 Feb 22. doi: 10.1111/hiv.13261.
    PubMed     Abstract available


  97. ASHRAF AN, Okhai H, Sabin CA, Sherr L, et al
    Obesity in women living with HIV aged 45-60 in England: An analysis of the PRIME study.
    HIV Med. 2022 Feb 18. doi: 10.1111/hiv.13242.
    PubMed     Abstract available


  98. COURVOISIER N, Storari C, Lesage S, Vittoz L, et al
    Facilitators and barriers of women's participation in HIV clinical research in Switzerland: A qualitative study.
    HIV Med. 2022 Feb 18. doi: 10.1111/hiv.13259.
    PubMed     Abstract available


  99. RASI V, Peters H, Sconza R, Francis K, et al
    Trends in antiretroviral use in pregnancy in the UK and Ireland, 2008-2018.
    HIV Med. 2022 Feb 18. doi: 10.1111/hiv.13243.
    PubMed     Abstract available


  100. CRESSWELL F, Asanati K, Bhagani S, Boffito M, et al
    UK guideline for the use of HIV post-exposure prophylaxis 2021.
    HIV Med. 2022 Feb 14. doi: 10.1111/hiv.13208.
    PubMed     Abstract available


  101. GUPTA R, Kaur A, Sandeep, Singh S, et al
    Anal cytological abnormalities and human papillomavirus infection in women living with HIV: A systematic review and meta-analysis.
    HIV Med. 2022 Feb 12. doi: 10.1111/hiv.13227.
    PubMed     Abstract available


  102. HANNA J, Sufian J, Suh JS, Jimenez HR, et al
    Hepatitis Cvirusmicro-elimination within a clinic for people with HIV:challenges in thehomestretch.
    HIV Med. 2022 Feb 12. doi: 10.1111/hiv.13241.
    PubMed     Abstract available


  103. INCEER M, Brouillette MJ, Fellows LK, Morais JA, et al
    Factors partitioning physical frailty in people aging with HIV: A classification and regression tree approach.
    HIV Med. 2022 Feb 1. doi: 10.1111/hiv.13236.
    PubMed     Abstract available


    January 2022
  104. WENLOCK RD, Shillingford C, Mear J, Churchill D, et al
    The impact of COVID-19 on HIV testing in the UK's first Fast-Track HIV city.
    HIV Med. 2022 Jan 30. doi: 10.1111/hiv.13235.
    PubMed     Abstract available


  105. WAHOME E, Boyd A, Thiong'o AN, Mohamed K, et al
    Stopping and restarting PrEP and loss to follow-up among PrEP-taking men who have sex with men and transgender women at risk of HIV-1 participating in a prospective cohort study in Kenya.
    HIV Med. 2022 Jan 27. doi: 10.1111/hiv.13237.
    PubMed     Abstract available


  106. AVELINO-SILVA VI, Vasconcelos R, Cerqueira NB, Marcus U, et al
    Predictors of knowledge of and access to biomedical prevention among MSM and transgender men in Latin America: Results from the Latin American internet survey.
    HIV Med. 2022 Jan 23. doi: 10.1111/hiv.13238.
    PubMed     Abstract available


  107. ADLER Z, Fitzpatrick C, Broadwell N, Churchill D, et al
    Chemsex and antiretroviral prescribing in an HIV cohort in Brighton, UK.
    HIV Med. 2022 Jan 20. doi: 10.1111/hiv.13239.
    PubMed     Abstract available


  108. FANCIULLI C, Berenguer J, Busca C, Vivancos MJ, et al
    Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019.
    HIV Med. 2022 Jan 17. doi: 10.1111/hiv.13229.
    PubMed     Abstract available


  109. BRIJKUMAR J, Edwards JA, Johnson BA, Ordonez C, et al
    Comparing effectiveness of first-line antiretroviral therapy between peri-urban and rural clinics in KwaZulu-Natal, South Africa.
    HIV Med. 2022 Jan 12. doi: 10.1111/hiv.13231.
    PubMed     Abstract available


  110. AFFI R, Gabillard D, Kouame GM, Ntakpe JB, et al
    Plasma sVCAM-1, antiretroviral therapy and mortality in HIV-1-infected West African adults.
    HIV Med. 2022 Jan 12. doi: 10.1111/hiv.13230.
    PubMed     Abstract available


  111. KOW CS, Ramachandram DS, Hasan SS
    The use of tenofovir in patients with COVID-19.
    HIV Med. 2022 Jan 12. doi: 10.1111/hiv.13228.
    PubMed    


  112. HARDING R, Jones CI, Bremner S, Bristowe K, et al
    Positive Outcomes: Validity, reliability and responsiveness of a novel person-centred outcome measure for people with HIV.
    HIV Med. 2022 Jan 11. doi: 10.1111/hiv.13224.
    PubMed     Abstract available


  113. SABIN C
    A new year, and big changes for HIV Medicine.
    HIV Med. 2022;23:3.
    PubMed    


    December 2021
  114. VAN LETTOW M, Tippett Barr BA, van Oosterhout JJ, Schouten E, et al
    The National Evaluation of Malawi's PMTCT Program (NEMAPP) study: 24-month HIV-exposed infant outcomes from a prospective cohort study.
    HIV Med. 2021 Dec 30. doi: 10.1111/hiv.13209.
    PubMed     Abstract available


  115. NDEGE RC, Okuma J, Kalinjuma AV, Mkumbo J, et al
    Failure to return pillbox is a predictor of being lost to follow-up among people living with HIV on antiretroviral therapy in rural Tanzania.
    HIV Med. 2021 Dec 28. doi: 10.1111/hiv.13223.
    PubMed     Abstract available


  116. MARQUES-GOMES J, Salt MJ, Pereira-Neto R, Barteldes FS, et al
    Development of the HIV360 international core set of outcome measures for adults living with HIV: A consensus process.
    HIV Med. 2021 Dec 28. doi: 10.1111/hiv.13221.
    PubMed     Abstract available


  117. FOKAM J, Mpouel Bala ML, Santoro MM, Takou D, et al
    Archiving of mutations in HIV-1 cellular reservoirs among vertically infected adolescents is contingent with clinical stages and plasma viral load: Evidence from the EDCTP-READY study.
    HIV Med. 2021 Dec 23. doi: 10.1111/hiv.13220.
    PubMed     Abstract available


  118. WILLIS SJ, Kim HN, Achenbach CJ, Cachay ER, et al
    Hepatitis C coinfection and extrahepatic cancer incidence among people living with HIV.
    HIV Med. 2021 Dec 23. doi: 10.1111/hiv.13218.
    PubMed     Abstract available


  119. WHITE HA, Okhai H, Kirwan P, Rafeeq SH, et al
    Tuberculosis incidence in country of origin is a key determinant of the risk of active tuberculosis in people living with HIV: Data from a 30-year observational cohort study.
    HIV Med. 2021 Dec 22. doi: 10.1111/hiv.13222.
    PubMed     Abstract available


  120. MUIRU AN, Madden E, Chilingirian A, Rubinsky AD, et al
    The incidence of and risk factors for hospitalized acute kidney injury among people living with HIV on antiretroviral treatment.
    HIV Med. 2021 Dec 12. doi: 10.1111/hiv.13216.
    PubMed     Abstract available


  121. MOCROFT A, Miro JM, Wandeler G, Llibre JM, et al
    The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study.
    HIV Med. 2021 Dec 9. doi: 10.1111/hiv.13210.
    PubMed     Abstract available


  122. AMELE S, Sandri AK, Rodger A, Vandekerckhove L, et al
    HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe.
    HIV Med. 2021 Dec 9. doi: 10.1111/hiv.13212.
    PubMed     Abstract available


  123. CAMPBELL L, Ibrahim F, Barbini B, Samarawickrama A, et al
    Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir.
    HIV Med. 2021 Dec 5. doi: 10.1111/hiv.13215.
    PubMed     Abstract available


  124. LAKATOS B, Kowalska J, Antoniak S, Gokengin D, et al
    Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug-drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19).
    HIV Med. 2021 Dec 3. doi: 10.1111/hiv.13214.
    PubMed     Abstract available


  125. KAEWPOOWAT Q, Rerkasem A, Rerkasem K, Robertson KR, et al
    Cardio-ankle vascular index of increased arterial wall stiffness is associated with neurocognitive impairment in well-controlled HIV.
    HIV Med. 2021 Dec 3. doi: 10.1111/hiv.13213.
    PubMed     Abstract available


  126. REEVES I, Cromarty B, Deayton J, Dhairyawan R, et al
    British HIV Association guidelines for the management of HIV-2 2021.
    HIV Med. 2021;22 Suppl 4:1-29.
    PubMed    


    November 2021
  127. NAITO T, Suzuki M, Fukushima S, Yuda M, et al
    Comorbidities and co-medications among 28 089 people living with HIV: A nationwide cohort study from 2009 to 2019 in Japan.
    HIV Med. 2021 Nov 25. doi: 10.1111/hiv.13206.
    PubMed     Abstract available


  128. HAN WM, Law MG, Choi JY, Ditangco R, et al
    Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV.
    HIV Med. 2021 Nov 23. doi: 10.1111/hiv.13211.
    PubMed     Abstract available


  129. KADDU-MULINDWA D, Keuser L, Lesan V, Rissland J, et al
    IgG seroprevalence of COVID-19 among people living with HIV or at high risk of HIV in south-west Germany: A seroprevalence study.
    HIV Med. 2021 Nov 22. doi: 10.1111/hiv.13207.
    PubMed     Abstract available


  130. TARIQ S, Okhai H, Severn A, Sabin CA, et al
    Follicle-stimulating hormone in postmenopausal women living with HIV: a prevalence study.
    HIV Med. 2021 Nov 17. doi: 10.1111/hiv.13205.
    PubMed     Abstract available


  131. REYNOLDS Z, McCluskey SM, Moosa MYS, Gilbert RF, et al
    Who's slipping through the cracks? A comprehensive individual, clinical and health system characterization of people with virological failure on first-line HIV treatment in Uganda and South Africa.
    HIV Med. 2021 Nov 9. doi: 10.1111/hiv.13203.
    PubMed     Abstract available


  132. CUZIN L, Delobel P, Martin-Blondel G
    Letter to the editor.
    HIV Med. 2021 Nov 7. doi: 10.1111/hiv.13192.
    PubMed    


  133. O'NEIL PJ, Stafford KA, Ryscavage PA
    Assessing risk factors for hypertension in young adults with perinatally acquired HIV infection: A case-control study.
    HIV Med. 2021 Nov 2. doi: 10.1111/hiv.13199.
    PubMed     Abstract available


  134. SILVA-NASH J, Bordelon S, Searcy SA, Dare RK, et al
    Standardizing HIV post-exposure prophylaxis in the emergency department following sexual assault.
    HIV Med. 2021 Nov 2. doi: 10.1111/hiv.13196.
    PubMed     Abstract available


  135. JEDICKE N, Stankov MV, Cossmann A, Dopfer-Jablonka A, et al
    Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy.
    HIV Med. 2021 Nov 2. doi: 10.1111/hiv.13202.
    PubMed     Abstract available


  136. RICHARDSON D, Nichols K, Hughes R, Smith H, et al
    The characteristics of men who have sex with men (MSM) using post-exposure prophylaxis for sexual exposure (PEPSE) in the pre-exposure prophylaxis (PrEP) era.
    HIV Med. 2021 Nov 2. doi: 10.1111/hiv.13201.
    PubMed     Abstract available


    October 2021
  137. CASTILLO-MANCILLA JR, Musinguzi N, Asiimwe S, Siedner MJ, et al
    High residual inflammation despite HIV viral suppression: Lessons learned from real-time adherence monitoring among people with HIV in Africa.
    HIV Med. 2021 Oct 26. doi: 10.1111/hiv.13200.
    PubMed     Abstract available


  138. JILICH D, Skrzat-Klapaczynska A, Fleischhans L, Bursa D, et al
    National strategies for vaccination against COVID-19 in people living with HIV in Central and Eastern European region.
    HIV Med. 2021 Oct 26. doi: 10.1111/hiv.13194.
    PubMed     Abstract available


  139. LARSON D, Won SH, Ganesan A, Maves RC, et al
    Statin usage and cardiovascular risk among people living with HIV in the U.S. Military HIV Natural History Study.
    HIV Med. 2021 Oct 26. doi: 10.1111/hiv.13195.
    PubMed     Abstract available


  140. JONES HT, Samji A, Cope N, Williams J, et al
    What problems associated with ageing are seen in a specialist service for older people living with HIV?
    HIV Med. 2021 Oct 25. doi: 10.1111/hiv.13193.
    PubMed     Abstract available


  141. CORKER E, Lorencatto F, Anderson N, Gobin M, et al
    Acceptability and facilitators of and barriers to point-of-care HIV testing in a homeless-focused service in Gloucestershire: a qualitative evaluation.
    HIV Med. 2021 Oct 24. doi: 10.1111/hiv.13187.
    PubMed     Abstract available


  142. LAJAUNIE R, Cuzin L, Palich R, Makinson A, et al
    No increased risk of Kaposi sarcoma relapse in patients with controlled HIV-1 infection after switching protease inhibitor-based antiretroviral therapy.
    HIV Med. 2021 Oct 19. doi: 10.1111/hiv.13168.
    PubMed     Abstract available


  143. SILVERSTEIN A, Kamiyango W, Villiera J, Peckham-Gregory EC, et al
    Long-term outcomes for children and adolescents with Kaposi sarcoma.
    HIV Med. 2021 Oct 11. doi: 10.1111/hiv.13191.
    PubMed     Abstract available


  144. VASCONCELOS R, Avelino-Silva VI, de Paula IA, Jamal LF, et al
    HIV self-test: a tool to expand test uptake among men who have sex with men who have never been tested for HIV in Sao Paulo, Brazil.
    HIV Med. 2021 Oct 11. doi: 10.1111/hiv.13178.
    PubMed     Abstract available


  145. NITPOLPRASERT C, Anand T, Phanuphak N, Reiss P, et al
    A qualitative study of the impact of coronavirus disease (COVID-19) on psychological and financial wellbeing and engagement in care among men who have sex with men living with HIV in Thailand.
    HIV Med. 2021 Oct 11. doi: 10.1111/hiv.13190.
    PubMed     Abstract available


  146. JONES TPW, Lampe FC, Arenas-Pinto A, Smith C, et al
    Alcohol, smoking, recreational drug use and association with virological outcomes among people living with HIV: cross-sectional and longitudinal analyses.
    HIV Med. 2021 Oct 11. doi: 10.1111/hiv.13156.
    PubMed     Abstract available


  147. BURNS JE, Stirrup O, Waters L, Dunn D, et al
    No overall impact on rate of weight gain with integrase inhibitor-containing regimens in antiretroviral-naive adults.
    HIV Med. 2021 Oct 11. doi: 10.1111/hiv.13186.
    PubMed     Abstract available


  148. TUAN JJ, Zapata H, Critch-Gilfillan T, Ryall L, et al
    Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV.
    HIV Med. 2021 Oct 10. doi: 10.1111/hiv.13188.
    PubMed     Abstract available


  149. RICK F, Odoke W, van den Hombergh J, Benzaken AS, et al
    Impact of coronavirus disease (COVID-19) on HIV testing and care provision across four continents.
    HIV Med. 2021 Oct 10. doi: 10.1111/hiv.13180.
    PubMed     Abstract available


  150. BROWN JA, Nsakala BL, Mokhele K, Rakuoane I, et al
    Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study).
    HIV Med. 2021 Oct 10. doi: 10.1111/hiv.13189.
    PubMed     Abstract available


  151. TUFA TB, Fuchs A, Orth HM, Lubke N, et al
    Characterization of HIV-1 drug resistance among patients with failure of second-line combined antiretroviral therapy in central Ethiopia.
    HIV Med. 2021 Oct 7. doi: 10.1111/hiv.13176.
    PubMed     Abstract available


  152. HOVAGUIMIAN F, Martin E, Reinacher M, Rasi M, et al
    Participation, retention and uptake in a multicentre pre-exposure prophylaxis cohort using online, smartphone-compatible data collection.
    HIV Med. 2021 Oct 3. doi: 10.1111/hiv.13175.
    PubMed     Abstract available


  153. CHAPPELL E, Kohns Vasconcelos M, Goodall RL, Galli L, et al
    Children living with HIV in Europe: do migrants have worse treatment outcomes?
    HIV Med. 2021 Oct 1. doi: 10.1111/hiv.13177.
    PubMed     Abstract available



  154. Abstracts of the 18th European AIDS Conference (EACS 2021), Online & London, United Kingdom, October 27-30, 2021.
    HIV Med. 2021;22 Suppl 3:4-309.
    PubMed    


    September 2021
  155. GRIMSHAW C, Boyd L, Smith M, Estcourt CS, et al
    Evaluation of an inner city HIV pre-exposure prophylaxis service tailored to the needs of people who inject drugs.
    HIV Med. 2021 Sep 28. doi: 10.1111/hiv.13181.
    PubMed     Abstract available


  156. WONG IKJ, Grulich AE, Poynten IM, Polizzotto MN, et al
    Time trends in cancer incidence in Australian people living with HIV between 1982 and 2012.
    HIV Med. 2021 Sep 28. doi: 10.1111/hiv.13179.
    PubMed     Abstract available


  157. LEE MJ, Snell LB, Douthwaite ST, Fidler S, et al
    Clinical outcomes of patients with and without HIV hospitalized with COVID-19 in England during the early stages of the pandemic: a matched retrospective multi-centre analysis (RECEDE-C19 study).
    HIV Med. 2021 Sep 23. doi: 10.1111/hiv.13174.
    PubMed     Abstract available


  158. MAZZITELLI M, Branca Isabel P, Muramatsu T, Chirwa M, et al
    FRAX assessment in people ageing with HIV.
    HIV Med. 2021 Sep 19. doi: 10.1111/hiv.13170.
    PubMed     Abstract available


  159. BROWN AE, Croxford SE, Nash S, Khawam J, et al
    COVID-19 mortality among people with diagnosed HIV compared to those without during the first wave of the COVID-19 pandemic in England.
    HIV Med. 2021 Sep 15. doi: 10.1111/hiv.13167.
    PubMed     Abstract available


  160. BURKE RM, Rickman HM, Singh V, Kalua T, et al
    Same-day antiretroviral therapy initiation for people living with HIV who have tuberculosis symptoms: a systematic review.
    HIV Med. 2021 Sep 15. doi: 10.1111/hiv.13169.
    PubMed     Abstract available


  161. VENKATESH KK, Edmonds A, Westreich D, Dionne-Odom J, et al
    Associations between HIV, antiretroviral therapy and preterm birth in the US Women's Interagency HIV Study, 1995-2018: a prospective cohort.
    HIV Med. 2021 Sep 12. doi: 10.1111/hiv.13171.
    PubMed     Abstract available


  162. BONOU M, Kapelios CJ, Protogerou AD, Mavrogeni S, et al
    Cardiac adiposity as a modulator of cardiovascular disease in HIV.
    HIV Med. 2021 Sep 12. doi: 10.1111/hiv.13166.
    PubMed     Abstract available


  163. CHOI JY, Lui GCY, Liao CT, Yang CJ, et al
    Managing cardiovascular risk in people living with HIV in Asia - where are we now?
    HIV Med. 2021 Sep 7. doi: 10.1111/hiv.13164.
    PubMed     Abstract available


  164. LAHER AE, Paruk F, Venter WDF, Ayeni OA, et al
    Development and internal validation of the HIV In-hospital Mortality Prediction (HIV-IMP) risk score.
    HIV Med. 2021 Sep 5. doi: 10.1111/hiv.13159.
    PubMed     Abstract available


  165. HACHFELD A, Atkinson A, Calmy A, de Tejada BM, et al
    Decrease of condom use in heterosexual couples and its impact on pregnancy rates: the Swiss HIV Cohort Study (SHCS).
    HIV Med. 2021 Sep 2. doi: 10.1111/hiv.13152.
    PubMed     Abstract available


  166. TARAMASSO L, Bonfanti P, Ricci E, Maggi P, et al
    Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade.
    HIV Med. 2021 Sep 2. doi: 10.1111/hiv.13165.
    PubMed     Abstract available


  167. LEAKE DATE HA, Alford K, Hounsome N, Moore D, et al
    Structured medicines reviews in HIV outpatients: a feasibility study (The MOR Study).
    HIV Med. 2021 Sep 1. doi: 10.1111/hiv.13158.
    PubMed     Abstract available


  168. KRAEF C, Bentzon A, Skrahina A, Mocroft A, et al
    Improving healthcare for patients with HIV, tuberculosis and hepatitis C in eastern Europe: a review of current challenges and important next steps.
    HIV Med. 2021 Sep 1. doi: 10.1111/hiv.13163.
    PubMed     Abstract available


    August 2021
  169. SPARKS E, Zorzela L, Necyk C, Hughes C, et al
    Study of natural product adverse events in adult HIV-infected patients in Canada.
    HIV Med. 2021 Aug 25. doi: 10.1111/hiv.13155.
    PubMed     Abstract available


  170. WHITLOCK GG, Protopapas K, Bernardino JI, Imaz A, et al
    Chems4EU: chemsex use and its impacts across four European countries in HIV-positive men who have sex with men attending HIV services.
    HIV Med. 2021 Aug 25. doi: 10.1111/hiv.13160.
    PubMed     Abstract available


  171. SANDERS EJ, Agutu C, van der Elst E, Hassan A, et al
    Effect of an opt-out point-of-care HIV-1 nucleic acid testing intervention to detect acute and prevalent HIV infection in symptomatic adult outpatients and reduce HIV transmission in Kenya: a randomized controlled trial.
    HIV Med. 2021 Aug 25. doi: 10.1111/hiv.13157.
    PubMed     Abstract available


  172. ANIKPO I, Agovi AM, Cvitanovich MJ, Lonergan F, et al
    The data-collection on adverse effects of anti-HIV drugs (D:A:D) model for predicting cardiovascular events: External validation in a diverse cohort of people living with HIV.
    HIV Med. 2021 Aug 19. doi: 10.1111/hiv.13147.
    PubMed     Abstract available


  173. CHALOUNI M, Pol S, Sogni P, Fontaine H, et al
    Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis.
    HIV Med. 2021 Aug 17. doi: 10.1111/hiv.13153.
    PubMed     Abstract available


  174. PINCUS KJ, Blackman AL, Suen SY, Devabhakthuni S, et al
    Statin gap in patients living with HIV: assessing dose appropriateness.
    HIV Med. 2021 Aug 8. doi: 10.1111/hiv.13150.
    PubMed     Abstract available


  175. FRANGE P, Blanche S, Veber F, Avettand-Fenoel V, et al
    Dolutegravir in the long term in children and adolescents: frequent virological failure but rare acquired genotypic resistance.
    HIV Med. 2021 Aug 8. doi: 10.1111/hiv.13154.
    PubMed     Abstract available



  176. Abstracts of the 5th Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH), Virtual, 19-21 April 2021.
    HIV Med. 2021;22 Suppl 2:3-126.
    PubMed    


    July 2021
  177. ROBERTS O, Kinvig H, Owen A, Lamorde M, et al
    In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel.
    HIV Med. 2021 Jul 30. doi: 10.1111/hiv.13136.
    PubMed     Abstract available


  178. LAWAL IO, Orunmuyi AT, Popoola GO, Mokoala KMG, et al
    Immune reconstitution inflammatory syndrome-associated Graves disease in HIV-infected patients: clinical characteristics and response to radioactive iodine therapy.
    HIV Med. 2021 Jul 30. doi: 10.1111/hiv.13148.
    PubMed     Abstract available


  179. DIEZ C, Del Romero-Raposo J, Mican R, Lopez JC, et al
    COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study.
    HIV Med. 2021 Jul 29. doi: 10.1111/hiv.13145.
    PubMed     Abstract available


  180. GIROMETTI N, Delpech V, McCormack S, Khawam J, et al
    The success of HIV combination prevention: The Dean Street model.
    HIV Med. 2021 Jul 29. doi: 10.1111/hiv.13149.
    PubMed     Abstract available


  181. FABBIANI M, Rossetti B, Ciccullo A, Oreni L, et al
    Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort.
    HIV Med. 2021 Jul 27. doi: 10.1111/hiv.13146.
    PubMed     Abstract available


  182. OKHAI H, Sabin CA, Haag K, Sherr L, et al
    Menopausal status, age and management among women living with HIV in the UK.
    HIV Med. 2021 Jul 26. doi: 10.1111/hiv.13138.
    PubMed     Abstract available


  183. SQUILLACE N, Bernasconi DP, Lapadula G, Soria A, et al
    HPV 16 and 18 contribute to development of anal dysplasia in HIV infection irrespective of gender and sexual orientation.
    HIV Med. 2021 Jul 22. doi: 10.1111/hiv.13143.
    PubMed     Abstract available


  184. BOEKE CE, Khan S, Walsh FJ, Lejeune C, et al
    Longitudinal analysis of client appointment adherence under Universal Test and Treat strategy: A stepped-wedge trial.
    HIV Med. 2021 Jul 22. doi: 10.1111/hiv.13144.
    PubMed     Abstract available


  185. SHARMA I
    Interrogating the impact of combination antiretroviral therapies on HIV-associated neurocognitive disorders.
    HIV Med. 2021 Jul 21. doi: 10.1111/hiv.13142.
    PubMed     Abstract available


  186. TORRES B, Guardo AC, Squarcia M, Diaz A, et al
    Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial.
    HIV Med. 2021 Jul 20. doi: 10.1111/hiv.13114.
    PubMed     Abstract available


  187. KIM JH, Noh J, Kim W, Seong H, et al
    Trends of age-related non-communicable diseases in people living with HIV and comparison with uninfected controls: A nationwide population-based study in South Korea.
    HIV Med. 2021 Jul 14. doi: 10.1111/hiv.13139.
    PubMed     Abstract available


  188. LEI JJH, Pereira B, Moyle G, Boffito M, et al
    The benefits of tenofovir discontinuation with or without bisphosphonate therapy in osteoporotic people living with HIV.
    HIV Med. 2021 Jul 13. doi: 10.1111/hiv.13137.
    PubMed     Abstract available


  189. WOLDESENBET SA, Kufa-Chakezha T, Lombard C, Manda S, et al
    Coverage of maternal viral load monitoring during pregnancy in South Africa: Results from the 2019 national Antenatal HIV Sentinel Survey.
    HIV Med. 2021 Jul 1. doi: 10.1111/hiv.13126.
    PubMed     Abstract available


  190. CHALOUNI M, Wittkop L, Bani-Sadr F, Lacombe K, et al
    Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants.
    HIV Med. 2021 Jul 1. doi: 10.1111/hiv.13127.
    PubMed     Abstract available


  191. CRAWFORD D, Allan B, Cogle A, Brown G, et al
    Client-led care in HIV: perspectives from community and practice.
    HIV Med. 2021;22 Suppl 1:3-14.
    PubMed     Abstract available


    June 2021
  192. LE XQ, Liu DP, Chen J, Gong ZY, et al
    Urinary biomarkers of early renal injury in antiretroviral-naive HIV-positive persons in Shanghai, China: comparison with the general population.
    HIV Med. 2021 Jun 10. doi: 10.1111/hiv.13123.
    PubMed     Abstract available


  193. MURRAY MM, Lin J, Buros Stein A, Wilcox ML, et al
    Relationship of polypharmacy to HIV RNA suppression in people aged >/= 50 years living with HIV.
    HIV Med. 2021 Jun 2. doi: 10.1111/hiv.13122.
    PubMed     Abstract available


  194. ZHABOKRITSKY A, Szadkowski L, Burchell AN, Cooper C, et al
    Immunological and virological response to initial antiretroviral therapy among older people living with HIV in the Canadian Observational Cohort (CANOC).
    HIV Med. 2021 Jun 1. doi: 10.1111/hiv.13125.
    PubMed     Abstract available


    May 2021
  195. KIM J, Nam HJ, Kang SJ, Jung SI, et al
    Integrase strand transfer inhibitor treatment does not increase the incidence of immune reconstitution inflammatory syndrome in HIV-infected Koreans.
    HIV Med. 2021 May 28. doi: 10.1111/hiv.13117.
    PubMed     Abstract available


  196. SCHULZ CA, Mavarani L, Reinsch N, Albayrak-Rena S, et al
    Prediction of future cardiovascular events by Framingham, SCORE and asCVD risk scores is less accurate in HIV-positive individuals from the HIV-HEART Study compared with the general population.
    HIV Med. 2021 May 24. doi: 10.1111/hiv.13124.
    PubMed     Abstract available


  197. MMASA KN, Powis K, Sun S, Makhema J, et al
    Gestational diabetes in women living with HIV in Botswana: lower rates with dolutegravir- than with efavirenz-based antiretroviral therapy.
    HIV Med. 2021 May 18. doi: 10.1111/hiv.13120.
    PubMed     Abstract available


  198. REGO DE FIGUEIREDO I, Branco Ferrao J, Dias S, Vieira Alves R, et al
    Tuberculosis infection in HIV vs. non-HIV patients.
    HIV Med. 2021 May 17. doi: 10.1111/hiv.13119.
    PubMed     Abstract available


  199. ALBASANZ-PUIG A, Suanzes P, Esperalba J, Fernandez C, et al
    Low frequency of cytomegalovirus (CMV) disease despite high prevalence of CMV viraemia in patients with advanced HIV infection: a clinical and immunological 48-week follow-up study.
    HIV Med. 2021 May 17. doi: 10.1111/hiv.13115.
    PubMed     Abstract available


  200. VORA J, Velhal S, Sinha S, Patel V, et al
    Bioactive phytocompound mulberroside C and endophytes of Morus alba as potential inhibitors of HIV-1 replication: a mechanistic evaluation.
    HIV Med. 2021 May 14. doi: 10.1111/hiv.13116.
    PubMed     Abstract available


  201. GILL MJ, Powell M, Vu Q, Krentz HB, et al
    Economic impact on direct healthcare costs of missing opportunities for diagnosing HIV within healthcare settings.
    HIV Med. 2021 May 12. doi: 10.1111/hiv.13121.
    PubMed     Abstract available


  202. FAN X, Fang J, Wu X, Poulsen K, et al
    Effect of HIV infection on pre- and post-liver transplant mortality in patients with organ failure.
    HIV Med. 2021 May 8. doi: 10.1111/hiv.13113.
    PubMed     Abstract available


  203. BURNS JE, Stohr W, Kinloch-De Loes S, Fox J, et al
    Tolerability of four-drug antiretroviral combination therapy in primary HIV-1 infection.
    HIV Med. 2021 May 8. doi: 10.1111/hiv.13118.
    PubMed     Abstract available


  204. PHALANE E, Fourie C, Schutte AE, Kruger IM, et al
    Arterial structure and function in Africans with HIV for > 5 years: longitudinal relationship with endothelial activation and cardiovascular risk markers.
    HIV Med. 2021 May 5. doi: 10.1111/hiv.13111.
    PubMed     Abstract available


  205. HOWARTH AR, Apea V, Michie S, Morris S, et al
    The association between use of chemsex drugs and HIV clinic attendance among gay and bisexual men living with HIV in London.
    HIV Med. 2021 May 5. doi: 10.1111/hiv.13103.
    PubMed     Abstract available


  206. ASAD H, Collins IJ, Goodall RL, Crichton S, et al
    Mortality and AIDS-defining events among young people following transition from paediatric to adult HIV care in the UK.
    HIV Med. 2021 May 3. doi: 10.1111/hiv.13096.
    PubMed     Abstract available


    April 2021
  207. RICHARDSON D, Nichols K, Pickering A, Devlin J, et al
    Transitioning from HIV post-exposure prophylaxis to pre-exposure prophylaxis in men who have sex with men.
    HIV Med. 2021 Apr 30. doi: 10.1111/hiv.13112.
    PubMed    


  208. JANSEN N, Daniels C, Sunil T, Xu X, et al
    Factors associated with erectile dysfunction diagnosis in men with HIV infection: a case-control study.
    HIV Med. 2021 Apr 25. doi: 10.1111/hiv.13107.
    PubMed     Abstract available


  209. KOVARI H, Surial B, Tarr PE, Cavassini M, et al
    Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.
    HIV Med. 2021 Apr 20. doi: 10.1111/hiv.13106.
    PubMed     Abstract available


  210. PATEL PG, Keen P, McManus H, Duck T, et al
    Increased targeted HIV testing and reduced undiagnosed HIV infections among gay and bisexual men.
    HIV Med. 2021 Apr 19. doi: 10.1111/hiv.13102.
    PubMed     Abstract available


  211. EZEAMAMA AE, Zalwango SK, Sikorskii A, Tuke R, et al
    In utero and peripartum antiretroviral exposure as predictor of cognition in 6- to 10-year-old HIV-exposed Ugandan children - a prospective cohort study.
    HIV Med. 2021 Apr 16. doi: 10.1111/hiv.13094.
    PubMed     Abstract available


  212. SAUMOY M, Di Yacovo S, Perez S, Sanchez-Quesada JL, et al
    Carotid atherosclerosis in virologically suppressed HIV patients: comparison with a healthy sample and prediction by cardiovascular risk equations.
    HIV Med. 2021 Apr 5. doi: 10.1111/hiv.13093.
    PubMed     Abstract available


    March 2021
  213. LAHER AE, Paruk F, Venter W, Ayeni OA, et al
    Predictors of in-hospital mortality among HIV-positive patients presenting with an acute illness to the emergency department.
    HIV Med. 2021 Mar 31. doi: 10.1111/hiv.13097.
    PubMed     Abstract available


  214. FOKAM J, Takou D, Njume D, Pabo W, et al
    Alarming rates of virological failure and HIV-1 drug resistance amongst adolescents living with perinatal HIV in both urban and rural settings: evidence from the EDCTP READY-study in Cameroon.
    HIV Med. 2021 Mar 31. doi: 10.1111/hiv.13095.
    PubMed     Abstract available


  215. NKUIZE M, Vanderpas J, Buset M, Delforge M, et al
    Failure to eradicate Helicobacter pylori infection is more frequent among HIV-positive patients.
    HIV Med. 2021 Mar 25. doi: 10.1111/hiv.13083.
    PubMed     Abstract available


  216. MASSAH G, Zhang W, Birungi J, Nanfuka M, et al
    Gender disparities operate in opposite directions for hospitalizations and mortality among individuals receiving long-term ART in rural Uganda.
    HIV Med. 2021 Mar 17. doi: 10.1111/hiv.13080.
    PubMed     Abstract available


  217. CHAN P, Colby DJ, Kroon E, Sacdalan C, et al
    Clinical and laboratory impact of concomitant syphilis infection during acute HIV.
    HIV Med. 2021 Mar 17. doi: 10.1111/hiv.13079.
    PubMed     Abstract available


  218. KANDA N, Okamoto K, Okumura H, Mieno M, et al
    Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan.
    HIV Med. 2021 Mar 15. doi: 10.1111/hiv.13061.
    PubMed     Abstract available


  219. D'SOUZA G, Benning L, Stosor V, Witt MD, et al
    The shifting picture of HIV treatment, comorbidity and substance use among US MSM living with HIV.
    HIV Med. 2021 Mar 10. doi: 10.1111/hiv.13082.
    PubMed     Abstract available


  220. ASCHER SB, Scherzer R, Estrella MM, Muiru AN, et al
    Kidney tubule health scores and their associations with incident CKD in women living with HIV.
    HIV Med. 2021 Mar 9. doi: 10.1111/hiv.13081.
    PubMed     Abstract available


    February 2021
  221. JESPERSEN NA, Axelsen F, Dollerup J, Norgaard M, et al
    The burden of non-communicable diseases and mortality in people living with HIV (PLHIV) in the pre-, early- and late-HAART era.
    HIV Med. 2021 Feb 28. doi: 10.1111/hiv.13077.
    PubMed     Abstract available


  222. PUNEKAR YS, Parks D, Joshi M, Kaur S, et al
    Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence.
    HIV Med. 2021 Feb 2. doi: 10.1111/hiv.13050.
    PubMed     Abstract available


  223. YANAVICH C, Pacheco AG, Cardoso SW, Nunes EP, et al
    Diagnostic value of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV.
    HIV Med. 2021 Feb 2. doi: 10.1111/hiv.13060.
    PubMed     Abstract available


  224. CROXFORD S, Burns F, Copas A, Yin Z, et al
    Trends and predictors of linkage to HIV outpatient care following diagnosis in the era of expanded testing in England, Wales and Northern Ireland: Results of a national cohort study.
    HIV Med. 2021 Feb 2. doi: 10.1111/hiv.13078.
    PubMed     Abstract available


    January 2021
  225. BOOTON RD, Ong JJ, Lee A, Liu A, et al
    Modelling the impact of an HIV testing intervention on HIV transmission among men who have sex with men in China.
    HIV Med. 2021 Jan 28. doi: 10.1111/hiv.13063.
    PubMed     Abstract available


  226. ARMENIA D, Bouba Y, Gagliardini R, Fabeni L, et al
    Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice.
    HIV Med. 2021 Jan 21. doi: 10.1111/hiv.13062.
    PubMed     Abstract available


  227. NOCELLA C, Mezzaroma I, Cammisotto V, Castellani V, et al
    Lipopolysaccharide induces platelet activation in HIV patients: the role of different viral load patterns.
    HIV Med. 2021 Jan 10. doi: 10.1111/hiv.13059.
    PubMed     Abstract available


  228. XU X, Lin H, Chen X, Zhu B, et al
    Differences in hypertension and prehypertension among people living with and without HIV in China: role of HIV infection and antiretroviral therapy.
    HIV Med. 2021 Jan 9. doi: 10.1111/hiv.13040.
    PubMed     Abstract available


  229. HORN C, Augustin M, Ercanoglu MS, Heger E, et al
    HIV DNA reservoir and elevated PD-1 expression of CD4 T-cell subsets particularly persist in the terminal ileum of HIV-positive patients despite cART.
    HIV Med. 2021 Jan 9. doi: 10.1111/hiv.13031.
    PubMed     Abstract available


  230. JABLONOWSKA E, Szetela B, Bielecki M, Horban A, et al
    Acquired immune deficiency syndrome (AIDS) and late presentation in Poland - data from Test and Keep in Care (TAK) Polska project.
    HIV Med. 2021 Jan 6. doi: 10.1111/hiv.13041.
    PubMed     Abstract available



  231. British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of Candidiasis 2019.
    HIV Med. 2021;22:73.
    PubMed    


  232. SABIN CA, Kunisaki KM, Bagkeris E, Post FA, et al
    Respiratory symptoms and chronic bronchitis in people with and without HIV infection.
    HIV Med. 2021;22:11-21.
    PubMed     Abstract available


  233. LEEME TB, Mine M, Lechiile K, Mulenga F, et al
    Utility of CD4 count measurement in the era of universal antiretroviral therapy: an analysis of routine laboratory data in Botswana.
    HIV Med. 2021;22:1-10.
    PubMed     Abstract available


  234. BOEKE CE, Khan S, Walsh F, Hettema A, et al
    Universal test and treat in relation to HIV disease progression: results from a stepped-wedge trial in Eswatini.
    HIV Med. 2021;22:54-59.
    PubMed     Abstract available


    December 2020
  235. HOFFMANN C, Casado JL, Harter G, Vizcarra P, et al
    Immune deficiency is a risk factor for severe COVID-19 in people living with HIV.
    HIV Med. 2020 Dec 27. doi: 10.1111/hiv.13037.
    PubMed     Abstract available


  236. GONZALEZ-SERNA A, Macias J, Palacios R, Gomez-Ayerbe C, et al
    Incidence of recently acquired hepatitis C virus infection among HIV-infected patients in southern Spain.
    HIV Med. 2020 Dec 26. doi: 10.1111/hiv.13039.
    PubMed     Abstract available


  237. BAXTER JD, Dunn D, Tostevin A, Marvig RL, et al
    Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study.
    HIV Med. 2020 Dec 25. doi: 10.1111/hiv.13038.
    PubMed     Abstract available


  238. REICHMUTH ML, Chaudron SE, Bachmann N, Nguyen H, et al
    Using longitudinally sampled viral nucleotide sequences to characterize the drivers of HIV-1 transmission.
    HIV Med. 2020 Dec 25. doi: 10.1111/hiv.13030.
    PubMed     Abstract available


  239. MCLEOD A, Hutchinson SJ, Smith S, Leen C, et al
    Increased case-finding and uptake of direct-acting antiviral treatment essential for micro-elimination of hepatitis C among people living with HIV: a national record linkage study.
    HIV Med. 2020 Dec 17. doi: 10.1111/hiv.13032.
    PubMed     Abstract available


  240. FIGUEROA MI, Camiro-Zuniga A, Belaunzaran-Zamudio PF, Sierra Madero J, et al
    The effect of protease inhibitor-based dual antiretroviral regimens on CD4/CD8 ratio during the first year of therapy in ART-naive patients with HIV-infection.
    HIV Med. 2020 Dec 17. doi: 10.1111/hiv.13008.
    PubMed     Abstract available


  241. BOGORODSKAYA M, Lyass A, Mahoney TF, Borowsky LH, et al
    Utilization of absolute monocyte counts to predict cardiovascular events in people living with HIV.
    HIV Med. 2020 Dec 8. doi: 10.1111/hiv.13018.
    PubMed     Abstract available


  242. TIAN Q, Si J, Jiang F, Xu R, et al
    Caspofungin combined with TMP/SMZ as a first-line therapy for moderate-to-severe PCP in patients with human immunodeficiency virus infection.
    HIV Med. 2020 Dec 4. doi: 10.1111/hiv.13013.
    PubMed     Abstract available


  243. HIREMATH PG, Bhondoekhan F, Haberlen SA, Ashikaga H, et al
    Testosterone use and shorter electrocardiographic QT interval duration in men living with and without HIV.
    HIV Med. 2020 Dec 3. doi: 10.1111/hiv.13029.
    PubMed     Abstract available


  244. CHADWICK DR, Sutherland RK, Raffe S, Pool E, et al
    British HIV Association guidelines on the management of opportunistic infection in people living with HIV: the clinical management of gastrointestinal opportunistic infections 2020.
    HIV Med. 2020;21 Suppl 5:1-19.
    PubMed    


  245. PALFREEMAN A, Sullivan A, Rayment M, Waters L, et al
    British HIV Association/British Association for Sexual Health and HIV/British Infection Association adult HIV testing guidelines 2020.
    HIV Med. 2020;21 Suppl 6:1-26.
    PubMed    


  246. LIU JY, Sun LQ, Hou YY, Wang LF, et al
    Barriers to early diagnosis and treatment of severely immunosuppressed patients with HIV-1 infection: A quantitative and qualitative study.
    HIV Med. 2020;21:708-717.
    PubMed     Abstract available


  247. HU W, Jiao YM, Wang FS
    Snapshot of clinical studies on people living with HIV in China.
    HIV Med. 2020;21:681-682.
    PubMed    


  248. YING RS, Le T, Cai WP, Li YR, et al
    Clinical epidemiology and outcome of HIV-associated talaromycosis in Guangdong, China, during 2011-2017.
    HIV Med. 2020;21:729-738.
    PubMed     Abstract available


  249. ZHAO Y, Han MJ, Gan XM, Ma Y, et al
    Characteristics and viral suppression among people living with HIV from the National Free Antiretroviral Therapy Programme, 2019.
    HIV Med. 2020;21:701-707.
    PubMed     Abstract available


  250. QI TK, Chen J, Zhang RF, Liu L, et al
    A retrospective cohort study of early mortality among patients with HIV/TB co-infection in Shanghai municipality.
    HIV Med. 2020;21:739-746.
    PubMed     Abstract available


  251. ZHANG C, Hu W, Jin JH, Zhou MJ, et al
    The role of CD8 T cells in controlling HIV beyond the antigen-specific face.
    HIV Med. 2020;21:692-700.
    PubMed     Abstract available


  252. LIU A, Zhang L, Zhang X, Zhang HW, et al
    Delayed seroreversion of specifical antibody against HIV in HIV-exposed infants: A retrospective cohort study.
    HIV Med. 2020;21:718-721.
    PubMed     Abstract available


  253. LIN L, Li TS
    Multidisciplinary collaborative integrated management of increasingly prominent HIV complications in the post-cART era.
    HIV Med. 2020;21:683-691.
    PubMed     Abstract available


  254. LI JH, Ma J, Kang W, Wang CF, et al
    The histone deacetylase inhibitor chidamide induces intermittent viraemia in HIV-infected patients on suppressive antiretroviral therapy.
    HIV Med. 2020;21:747-757.
    PubMed     Abstract available


  255. JIANG TY, Hou JH, Su B, Zhang T, et al
    Demographic and clinical factors associated with immune reconstitution in HIV/HBV co-infected and HIV mono-infected patients: a retrospective cohort study.
    HIV Med. 2020;21:722-728.
    PubMed     Abstract available


    November 2020
  256. HSU R, Brunet L, Fusco J, Beyer A, et al
    Risk of chronic kidney disease in people living with HIV by tenofovir disoproxil fumarate (TDF) use and baseline D:A:D chronic kidney disease risk score.
    HIV Med. 2020 Nov 28. doi: 10.1111/hiv.13019.
    PubMed     Abstract available


  257. SIVARAJ V, Cliff P, Douthwaite S, Smith M, et al
    Pneumocystis jirovecii pneumonia PCR test on upper respiratory tract swab.
    HIV Med. 2020 Nov 23. doi: 10.1111/hiv.13014.
    PubMed     Abstract available


  258. BENTZON AK, Panteleev A, Mitsura V, Borodulina E, et al
    Healthcare delivery for HIV-positive people with tuberculosis in Europe.
    HIV Med. 2020 Nov 20. doi: 10.1111/hiv.13016.
    PubMed     Abstract available


  259. HAN WM, Jiamsakul A, Jantarapakde J, Yunihastuti E, et al
    Association of body mass index with immune recovery, virological failure and cardiovascular disease risk among people living with HIV.
    HIV Med. 2020 Nov 17. doi: 10.1111/hiv.13017.
    PubMed     Abstract available


  260. CUI Z, Huang H, Zhang T, Yu Z, et al
    Low awareness of and willingness to use PrEP in the Chinese YMSM: An alert in YMSM HIV prevention.
    HIV Med. 2020 Nov 16. doi: 10.1111/hiv.12990.
    PubMed     Abstract available


  261. SANMARTI M, Meyer AC, Jaen A, Robertson K, et al
    HIV-associated neurocognitive impairment in stable people living with HIV on ART in rural Tanzania.
    HIV Med. 2020 Nov 15. doi: 10.1111/hiv.12979.
    PubMed     Abstract available


  262. TRICKEY A, Stone J, Semchuk N, Saliuk T, et al
    Is contact between men who have sex with men and non-governmental organizations providing harm reduction associated with improved HIV outcomes?
    HIV Med. 2020 Nov 12. doi: 10.1111/hiv.13010.
    PubMed     Abstract available


  263. SARFO FS, Norman B, Nichols M, Appiah L, et al
    Prevalence and incidence of pre-diabetes and diabetes mellitus among people living with HIV in Ghana: Evidence from the EVERLAST Study.
    HIV Med. 2020 Nov 10. doi: 10.1111/hiv.13007.
    PubMed     Abstract available


  264. HANTTU A, Kauppinen KJ, Kivela P, Ollgren J, et al
    Prevalence of obesity and disturbances in glucose homeostasis in HIV-infected subjects and general population - missed diagnoses of diabetes?
    HIV Med. 2020 Nov 9. doi: 10.1111/hiv.13009.
    PubMed     Abstract available


  265. CHOUDHURY B, Brown J, Ransy DG, Brophy J, et al
    Endothelial activation is associated with intestinal epithelial injury, systemic inflammation and treatment regimen in children living with vertically acquired HIV-1 infection.
    HIV Med. 2020 Nov 5. doi: 10.1111/hiv.13012.
    PubMed     Abstract available


  266. BEANLAND A, Alagaratnam J, Goffe C, Bailey A, et al
    Objective and subjective rapid frailty screening tools in people with HIV.
    HIV Med. 2020 Nov 5. doi: 10.1111/hiv.12988.
    PubMed     Abstract available


  267. ROSS J, Jiamsakul A, Kumarasamy N, Azwa I, et al
    Virological failure and HIV drug resistance among adults living with HIV on second-line antiretroviral therapy in the Asia-Pacific.
    HIV Med. 2020 Nov 5. doi: 10.1111/hiv.13006.
    PubMed     Abstract available


  268. MORKPHROM E, Ratanasuwan W, Sittironnarit G, Rattanaumpawan P, et al
    Non-disclosure of HIV serostatus to sexual partners: Prevalence, risk factors and clinical impact in patients with HIV.
    HIV Med. 2020 Nov 3. doi: 10.1111/hiv.13005.
    PubMed     Abstract available


  269. PODA A, Kabore NF, Malateste K, De Rekeneire N, et al
    Validation of the D:A:D chronic kidney disease risk score in people living with HIV: the IeDEA West Africa Cohort Collaboration.
    HIV Med. 2020 Nov 3. doi: 10.1111/hiv.12982.
    PubMed     Abstract available


  270. TO KW, Lee SS
    A review of reported cases of HIV pre-exposure prophylaxis failure with resultant breakthrough HIV infections.
    HIV Med. 2020 Nov 3. doi: 10.1111/hiv.12989.
    PubMed     Abstract available



  271. Abstracts of the 26th Annual Conference of the British HIV Association (BHIVA), Digital Conference, 22nd-24th November 2020.
    HIV Med. 2020;21 Suppl 4:3-74.
    PubMed    


    October 2020
  272. PAUL G, Wesselmann J, Adzic D, Malin JJ, et al
    Predictors of serofast state after treatment for early syphilis in HIV-infected patients.
    HIV Med. 2020 Oct 30. doi: 10.1111/hiv.12985.
    PubMed     Abstract available


  273. FREGUJA R, Bamford A, Zanchetta M, Del Bianco P, et al
    Long-term clinical, virological and immunological outcomes following planned treatment interruption in HIV-infected children.
    HIV Med. 2020 Oct 29. doi: 10.1111/hiv.12986.
    PubMed     Abstract available


  274. FERNANDEZ I, de Lazzari E, Inciarte A, Diaz-Brito V, et al
    Network meta-analysis of post-exposure prophylaxis randomized clinical trials.
    HIV Med. 2020 Oct 27. doi: 10.1111/hiv.12964.
    PubMed     Abstract available


  275. MCALLISTER S, van Asten H, Anglemyer A, Crengle S, et al
    Cascade of care of people diagnosed with HIV in New Zealand between 2006 and 2017.
    HIV Med. 2020 Oct 27. doi: 10.1111/hiv.12983.
    PubMed     Abstract available


  276. KIRWAN PD, Hibbert M, Kall M, Nambiar K, et al
    HIV prevalence and HIV clinical outcomes of transgender and gender-diverse people in England.
    HIV Med. 2020 Oct 26. doi: 10.1111/hiv.12987.
    PubMed     Abstract available


  277. AUNG HL, Bloch M, Vincent T, Quan D, et al
    Cognitive ageing is premature among a community sample of optimally treated people living with HIV.
    HIV Med. 2020 Oct 21. doi: 10.1111/hiv.12980.
    PubMed     Abstract available


  278. GAZZOLA L, Tagliaferri G, De Bona A, Mondatore D, et al
    Dyslipidaemia after switch to tenofovir alafenamide (TAF)-based cART regimens in a cohort of HIV-positive patients: what clinical relevance?
    HIV Med. 2020 Oct 21. doi: 10.1111/hiv.12984.
    PubMed     Abstract available


  279. QUAH SP, McIntyre M, Wood A, Mc Mullan K, et al
    Once-daily raltegravir with tenofovir disoproxil/emtricitabine as HIV post-exposure prophylaxis following sexual exposure.
    HIV Med. 2020 Oct 16. doi: 10.1111/hiv.12938.
    PubMed    


  280. SCHUETTFORT G, Boekenkamp L, Cabello A, Cotter AG, et al
    Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors.
    HIV Med. 2020 Oct 13. doi: 10.1111/hiv.12962.
    PubMed     Abstract available


  281. WENGER DS, Triplette M, Shahrir S, Akgun KM, et al
    Associations of marijuana with markers of chronic lung disease in people living with HIV.
    HIV Med. 2020 Oct 6. doi: 10.1111/hiv.12966.
    PubMed     Abstract available


  282. VAUGHAN J, Perner Y, Mayne E, Wiggill T, et al
    Plasmablastic lymphoma in Johannesburg, South Africa, in the era of widescale antiretroviral therapy use.
    HIV Med. 2020 Oct 6. doi: 10.1111/hiv.12965.
    PubMed     Abstract available


  283. BALAYAN T, Begovac J, Skrzat-Klapaczynska A, Aho I, et al
    Where are we with pre-exposure prophylaxis use in Central and Eastern Europe? Data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group.
    HIV Med. 2020 Oct 5. doi: 10.1111/hiv.12960.
    PubMed     Abstract available


  284. ALMEIDA F, Macedo A, Trigo D, Abreu M, et al
    Neurocognitive evaluation using the International HIV Dementia Scale (IHDS) and Montreal Cognitive Assessment Test (MoCA) in an HIV-2 population.
    HIV Med. 2020 Oct 4. doi: 10.1111/hiv.12963.
    PubMed     Abstract available


  285. BLOCH M, John M, Smith D, Rasmussen TA, et al
    Managing HIV-associated inflammation and ageing in the era of modern ART.
    HIV Med. 2020;21 Suppl 3:2-16.
    PubMed     Abstract available


  286. IBRAHIM F, Campbell L, Bailey AC, Stockwell S, et al
    Estimated glomerular filtration rate slopes on tenofovir alafenamide.
    HIV Med. 2020;21:607-612.
    PubMed     Abstract available


  287. DRAVID A, Betha TP, Sharma AK, Gawali R, et al
    Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhi
    HIV Med. 2020;21:578-587.
    PubMed     Abstract available


    September 2020
  288. IBRAHIM F, Samarawickrama A, Hamzah L, Vincent R, et al
    Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG.
    HIV Med. 2020 Sep 27. doi: 10.1111/hiv.12961.
    PubMed     Abstract available


  289. BASIL RC, Brown TT, Haberlen S, Rubin LH, et al
    The relationship between diabetes and depressive symptoms in men with or at risk of HIV infection.
    HIV Med. 2020 Sep 24. doi: 10.1111/hiv.12958.
    PubMed     Abstract available


  290. BORGHETTI A, Ciccullo A, Lombardi F, Baldin G, et al
    Transmitted drug resistance to NRTIs and risk of virological failure in naive patients treated with integrase inhibitors.
    HIV Med. 2020 Sep 23. doi: 10.1111/hiv.12956.
    PubMed     Abstract available


  291. ADAMS JL, Murray M, Patel N, Sawkin MT, et al
    Comparative effectiveness of antiretroviral drug classes for the treatment of HIV infection in patients with high viral loads: a multicentre retrospective cohort study.
    HIV Med. 2020 Sep 23. doi: 10.1111/hiv.12959.
    PubMed     Abstract available


  292. KORTEN V, Ay U, Hari E, Tigen Tukenmez E, et al
    Prevalence of HIV-associated neurocognitive disorder (HAND) in Turkey and assessment of Addenbrooke's Cognitive Examination Revised (ACE-R) test as a screening tool.
    HIV Med. 2020 Sep 23. doi: 10.1111/hiv.12957.
    PubMed     Abstract available


  293. RYOM L, Cotter A, De Miguel R, Beguelin C, et al
    2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0.
    HIV Med. 2020 Sep 3. doi: 10.1111/hiv.12878.
    PubMed     Abstract available


  294. GIROMETTI N, Lander F, McOwan A, Nwokolo N, et al
    Rapid ART start in early HIV infection: Time to viral load suppression and retention in care in a London cohort.
    HIV Med. 2020 Sep 1. doi: 10.1111/hiv.12900.
    PubMed     Abstract available


    July 2020
  295. OKOLI C, Schwenk A, Radford M, Myland M, et al
    Polypharmacy and potential drug-drug interactions for people with HIV in the UK from the Climate-HIV database.
    HIV Med. 2020 Jul 15. doi: 10.1111/hiv.12879.
    PubMed     Abstract available


    June 2020
  296. MWASAKIFWA GE, Amin J, White CP, Center JR, et al
    Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LI
    HIV Med. 2020 Jun 23. doi: 10.1111/hiv.12882.
    PubMed     Abstract available


  297. GANTNER P, Allavena C, Duvivier C, Cabie A, et al
    Post-exposure prophylaxis completion and condom use in the context of potential sexual exposure to HIV.
    HIV Med. 2020 Jun 17. doi: 10.1111/hiv.12880.
    PubMed     Abstract available


  298. SCHRADER SY, Zeder AJ, Hilge R, Bogner JR, et al
    Medium-grade proteinuria is a risk factor for incident markers of chronic kidney disease.
    HIV Med. 2020 Jun 17. doi: 10.1111/hiv.12881.
    PubMed     Abstract available


    February 2020
  299. SCHWARZE-ZANDER C, Piduhn H, Boesecke C, Schlabe S, et al
    Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?
    HIV Med. 2020 Feb 17. doi: 10.1111/hiv.12840.
    PubMed     Abstract available


    January 2020
  300. STIRRUP OT, Asboe D, Pozniak A, Sabin CA, et al
    Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation.
    HIV Med. 2020 Jan 11. doi: 10.1111/hiv.12829.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: